Bristol-Myers Squibb (NYSE:BMY) launched a subcutaneous administration option for Orencia, a biologic indicated for moderately to severely active polyarticular juvenile idiopathic arthritis in patients who are at least 2 years old.
The prefilled syringe enables physicians, caregivers and patients to administer Orencia at home.
Get the full story at our sister site, Drug Delivery Business News.
The post Bristol-Myers Squibb launches prefilled syringe option for arthritis drug appeared first on MassDevice.